Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Front Public Health ; 10: 990708, 2022.
Article in English | MEDLINE | ID: covidwho-2055097

ABSTRACT

Ultrasound, as a common clinical examination tool, inevitably has human errors due to the limitations of manual operation. Artificial intelligence is an advanced computer program that can solve this problem. Therefore, the relevant literature on the application of artificial intelligence in the ultrasonic field from 2011 to 2021 was screened by authors from the Web of Science Core Collection, which aims to summarize the trend of artificial intelligence application in the field of ultrasound, meanwhile, visualize and predict research hotspots. A total of 908 publications were included in the study. Overall, the number of global publications is on the rise, and studies on the application of artificial intelligence in the field of ultrasound continue to increase. China has made the largest contribution in this field. In terms of institutions, Fudan University has the most number of publications. Recently, IEEE Access is the most published journal. Suri J. S. published most of the articles and had the highest number of citations in this field (29 articles). It's worth noting that, convolutional neural networks (CNN), as a kind of deep learning algorithm, was considered to bring better image analysis and processing ability in recent most-cited articles. According to the analysis of keywords, the latest keyword is "COVID-19" (2020.8). The co-occurrence analysis of keywords by VOSviewer visually presented four clusters which consisted of "deep learning," "machine learning," "application in the field of visceral organs," and "application in the field of cardiovascular". The latest hot words of these clusters were "COVID-19; neural-network; hepatocellular carcinoma; atherosclerotic plaques". This study reveals the importance of multi-institutional and multi-field collaboration in promoting research progress.


Subject(s)
Artificial Intelligence , COVID-19 , Bibliometrics , Humans , Neural Networks, Computer , Publications
2.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-325512

ABSTRACT

Background: The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 isspreading all over the world.The main symptoms of COVID-19 include fever, cough,fatigue, and myalgia. However, there are few reports onolfactoryand gustatory dysfunctions in patients with COVID-19. Objective: To investigate the incidence of olfactory and gustatory dysfunctions in patients with confirmed COVID-19 infection, in Wuhan, China. Methods: : In this retrospective study,we collected 81 confirmed cases of COVID-19 from the Renmin Hospital of Wuhan University, from February 2020 to March 2020, and analyzed the demographic characteristics, clinical manifestations (including olfactory and gustatory dysfunctions), laboratory findings,and comorbidities. Results: : A total of 81 confirmed COVID-19 patients were enrolledin this study (38 males). The most prevalent symptoms include cough, myalgia, and loss of appetite. On admission, 25 (30.9%) of all patients reported either olfactory dysfunction (OD) or gustatory dysfunction (GD), and 7 (8.6%) reported both OD and GD. 13.6% and 25.9% of allpatients reported OD and GD, respectively. OD and GD were not associated with disease severity. Pearson correlation analysisidentified some factors are positively correlated with OD and GD, including headache or dizziness (r = 0.342, P = 0.002), dark urine (r = 0.256, P = 0.021), IgM titer (r = 0.305, P = 0.01), and diabetes (r = 0.275, P = 0.013). In 81.8% of the cases with OD and 28.6% of the cases with GD, the symptomslasted for at least 1 month after discharge.3.6% of inpatients without OD developed OD after discharge. Conclusion: OD and GDare common in COVID-19.These symptoms appear early during thecourse of disease, and may last for at least 1 month.The incidence of OD and GDisrelated to neurological manifestations, diabetics, and IgM titers.

3.
Sleep Med ; 75: 428-433, 2020 11.
Article in English | MEDLINE | ID: covidwho-752846

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic is adversely affecting sleep quality and mental health, especially in individuals with chronic disease such as Parkinson's disease (PD). METHODS: We conducted a quantitative study, which included 119 Chinese PD patients who had been treated in an outpatient neurology clinic in Wuhan and 169 age- and sex-matched healthy controls. The questionnaire survey focused on the impact of the COVID-19 pandemic on sleep, mental status, symptoms, and daily life and medical treatment of PD patients. RESULTS: Compared to healthy controls, PD patients had significantly higher scores in both the Pittsburgh Sleep Quality Index (PSQI) (8.13 vs 5.36, p < 0.001) and the Hospital Anxiety and Depression Scale (HADS) -Depression (4.89 vs 3.82, p = 0.022), as well as a higher prevalence of sleep disturbances with PSQI > 5 points (68.9% vs 44.4%, p < 0.001). Sleep disturbance was identified in 68.9% of PD patients. A logistic regression analysis showed that sleep disturbance of PD patients was independently associated with exacerbation of PD symptoms (OR = 3.616, 95%CI= (1.479, 8.844), p = 0.005) and anxiety (OR = 1.379, 95%CI= (1.157, 1.642), p < 0.001). Compared to male PD patients, female ones had higher PSQI scores (9.28 ± 4.41 vs 7.03 ± 4.01, p = 0.009) and anxiety (32.8% vs 0.1%, p = 0.002) and depression prevalence (34.5% vs 11.5%, p = 0.003). CONCLUSION: The findings of the present study emphasize the importance of mental and sleep health interventions in PD patients during the COVID-19 pandemic. Additional attention should be paid to the difficulty encountered by PD patients in seeking medical treatment.


Subject(s)
Anxiety/epidemiology , COVID-19/psychology , Depression/epidemiology , Pandemics , Parkinson Disease/epidemiology , Sleep Initiation and Maintenance Disorders/epidemiology , Aged , Case-Control Studies , China , Cross-Sectional Studies , Disease Progression , Female , Humans , Male , Middle Aged , Parkinson Disease/psychology , Qualitative Research , Surveys and Questionnaires
4.
Front Med (Lausanne) ; 7: 532, 2020.
Article in English | MEDLINE | ID: covidwho-739251

ABSTRACT

Objective: To describe the clinical manifestations and outcomes of COVID-19, and explore the risk factors of deterioration and death of the disease. Methods: In this retrospective study, we collected data from 121 COVID-19 cases confirmed by RT-PCR and next-generation sequencing in Renmin Hospital of Wuhan University from January 30, 2019, to March 23, 2020, and conducted statistical analysis. Results: A total of 121 patients were included in our study, the median age was 65 years (IQR, 55.0-71.5 years), and 54.5% cases were men. Among those cases, 52 (43.0%) cases progressed to severe, and 14 (11.6%) died. Overall, the most common manifestations were fever (78.5%) and respiratory symptoms (77.7%), while neurological symptoms were found in only 9.9% of the patients. 70.2% of all the cases had comorbidities, including hypertension (40.5%) and diabetes (20.7%). On admission, cases usually show elevated levels of neutrophils (27.3%), D-dimer (72.6%), Interleukin-6 (35.2%), Interleukin-10 (64.4%), high-sensitivity C-reactive protein (82.6%), and lactate dehydrogenase (62.0%), and decreased levels of lymphocytes (66.9%), CD3 cells (67.2%), and CD4 cells (63.0%). The proportional hazard Cox models showed that the risk factors for severity progression and death included comorbidities (HR: 4.53, 95% CI: 1.78-11.55 and HR: 7.81, 95% CI: 1.02-59.86), leukocytosis (HR: 1.13; 95% CI: 1.05-1.22 and HR: 1.25, 95% CI: 1.10-1.42), neutrophilia (HR: 1.15, 95% CI: 1.07-1.13 and HR: 1.28, 95% CI: 1.13-1.46, and elevated LDH (HR: 1.14, 95% CI: 1.12-1.15 and HR: 1.11, 95% CI: 1.10-1.12). Elevated D-dimer (HR: 1.02, 95% CI: 1.01-1.03), IL-6 (HR: 1.01, 95% CI: 1.00-1.02) and IL-10 levels (HR: 1.04, 95% CI: 1.01-1.07) were also risk factors for the progression of disease severity. Meanwhile, lymphopenia and wake immune responses [e.g., lower CD3, CD4, or CD19 counts (all HR < 1)] were associated with disease deterioration and death. Conclusions: Severe cases and death of COVID-19 are associated with older age, comorbidities, organ dysfunction, lymphopenia, high cytokines, and weak immune responses.

5.
Arch Pharm Res ; 43(8): 765-772, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-692878

ABSTRACT

A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.


Subject(s)
Chloroquine/therapeutic use , Coronavirus Infections/drug therapy , Hydroxychloroquine/therapeutic use , Pneumonia, Viral/drug therapy , Antimalarials , COVID-19 , Humans , Pandemics
6.
Sleep Med ; 72: 1-4, 2020 08.
Article in English | MEDLINE | ID: covidwho-342920

ABSTRACT

OBJECTIVE: To evaluate sleep disturbances of Chinese frontline medical workers (FMW) under the outbreak of coronavirus disease 2019 (COVID-19), and make a comparison with non-FMW. METHODS: The medical workers from multiple hospitals in Hubei Province, China, volunteered to participate in this cross-sectional study. An online questionnaire, including Pittsburgh Sleep Quality Index (PSQI), Athens Insomnia Scale (AIS) and Visual Analogue Scale (VAS), was used to evaluate sleep disturbances and mental status. Sleep disturbances were defined as PSQI>6 points or/and AIS>6 points. We compared the scores of PSQI, AIS, anxiety and depression VAS, as well as prevalence of sleep disturbances between FMW and non-FMW. RESULTS: A total of 1306 subjects (801 FMW and 505 non-FMW) were enrolled. Compared to non-FMW, FMW had significantly higher scores of PSQI (9.3 ± 3.8 vs 7.5 ± 3.7; P < 0.001; Cohen's d = 0.47), AIS (6.9 ± 4.3 vs 5.3 ± 3.8; P < 0.001; Cohen's d = 0.38), anxiety (4.9 ± 2.7 vs 4.3 ± 2.6; P < 0.001; Cohen's d = 0.22) and depression (4.1 ± 2.5 vs 3.6 ± 2.4; P = 0.001; Cohen's d = 0.21), as well as higher prevalence of sleep disturbances according to PSQI > 6 points (78.4% vs 61.0%; relative risk [RR] = 1.29; P < 0.001) and AIS > 6 points (51.7% vs 35.6%; RR = 1.45; P < 0.001). CONCLUSION: FMW have higher prevalence of sleep disturbances and worse sleep quality than non-FMW. Further interventions should be administrated for FMW, aiming to maintain their healthy condition and guarantee their professional performance in the battle against COVID-19.


Subject(s)
Anxiety/epidemiology , Coronavirus Infections/epidemiology , Depression/epidemiology , Health Personnel/statistics & numerical data , Pneumonia, Viral/epidemiology , Sleep Initiation and Maintenance Disorders/epidemiology , Adult , Anxiety/psychology , Betacoronavirus , COVID-19 , Case-Control Studies , China/epidemiology , Cross-Sectional Studies , Depression/psychology , Disease Outbreaks , Female , Health Personnel/psychology , Humans , Male , Pandemics , Prevalence , SARS-CoV-2 , Sex Factors , Sleep Initiation and Maintenance Disorders/physiopathology , Sleep Initiation and Maintenance Disorders/psychology , Sleep Wake Disorders/epidemiology , Sleep Wake Disorders/physiopathology , Visual Analog Scale
7.
J Infect Dis ; 222(2): 183-188, 2020 06 29.
Article in English | MEDLINE | ID: covidwho-245018

ABSTRACT

BACKGROUND: A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged and caused the rapid spread of coronavirus disease 2019 (COVID-19) worldwide. METHODS: We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between 1 February and 29 February 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen. RESULTS: One hundred twelve patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both immunoglobulin M (IgM) and immunoglobulin G (IgG), 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post-disease onset, lasted for 1 month, and gradually decreased, whereas IgG antibody was produced 10 days after infection and lasted for a longer time. However, no significant difference in levels of IgM and IgG antibodies between positive and negative patients of nucleic acid test after treatment was found. CONCLUSIONS: Our results indicate that serological tests could be a powerful approach for the early diagnosis of COVID-19.


Subject(s)
Antibodies, Viral/blood , Betacoronavirus/immunology , Coronavirus Infections/diagnosis , Coronavirus Infections/immunology , Pneumonia, Viral/diagnosis , Pneumonia, Viral/immunology , Adult , Aged , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Disease Progression , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged , Pandemics , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2 , Serologic Tests
SELECTION OF CITATIONS
SEARCH DETAIL